AMZN rated Hold with $240 target (+15%). $717B revenue growing 12%, AWS +20%, but $128B AI capex collapsed FCF 71%. Wait for Q1 earnings clarity.
Related To: Options Trading
ALK rated Buy with $55 target (+52%). Crashed 54% on Iran/oil panic. 6.7x adj P/E, 0.7x P/B, $5.40 adjusted EPS. Hawaiian synergies coming.
DIS rated Buy with $120 target (+21%). 14.5x P/E, $18B OCF, parks +6% growth. Director Gorman buying $4.1M personally. CEO transition risk.
IONQ rated Hold with $34 target (+3%). Revenue tripled to $130M but 93x P/S, negative margins, and $335M coordinated insider selling.
RIVN rated Hold with $16 target (+8%). First gross profit year, R2 launching Q2 2026, but execution risk and cash burn remain concerns.
SMMT rated Speculative Hold. Binary FDA bet on ivonescimab — bull case $28-35, bear case $3-5. PDUFA Nov 14, 2026.
TMO rated Buy with $575 target (+22%). Forward P/E 17.5x cheapest since March 2020. $6.3B FCF, Life Sciences recovery, RSI deeply oversold at 28.
I’m building a growing library of in-depth stock analysis reports covering fundamentals, technicals, SEC filings, and sentiment. Launching today with six, many more on the way.
BE is a HOLD at $154.51. AI data center power thesis is real, but 21x P/S and lopsided insider selling mean risk/reward is unfavorable.
BROS rated Buy with $68 target (+44% upside). 28% revenue growth, transaction-driven comps, and a 4,000+ store runway offset insider selling headwinds.
